Empowering Patients, Enhancing Safety
In an age where patient safety is non-negotiable, we are helping to transform pharmacovigilance (PV) processes with our cutting-edge AI accelerators and solutions. By integrating advanced digital technology with seasoned human expertise, we provide a comprehensive outlook on product safety profiles and elevate patient safety measures.
As part of our commitment to advancing drug safety, we are excited to participate in the upcoming DIA China 2024, a global network of experts dedicated to enhancing global health innovation. The HCLTech Global Pharmacovigilance and Epidemiology (GPV&E) team will showcase how we effectively capture, analyze and aggregate a rich 360° view of healthcare products' safety profiles.
Join us at booth CA11 to explore how HCLTech offers a comprehensive suite of services encompassing R&D, preclinical trials, clinical procedures, regulatory affairs, pharmacovigilance and medical information management.
Advancing PV with Next-gen Solutions
Harnessing the power of AI, our pharmacovigilance solutions streamline case intake, automate intelligent aggregate and risk mitigation action plan (RMP) authoring, enable efficient adverse event identification and ensure robust quality control. By leveraging advanced AI algorithms, our solutions enhance the entire pharmacovigilance process, making it more efficient and effective.
Our Analyst Recognitions
HCLTech rated as a Leader in ISG Provider Lens™ - Healthcare Digital Services, U.S. 2023
HCLTech Positioned As A Leader In Everest Group’s Life Sciences Digital Services PEAK Matrix® Assessment 2022
HCLTech Positioned as a Leader in Unstructured Document Processing Products PEAK Matrix® Assessment 2023
Our Resources
Latest AI News
April 3, 2024
HCLTech launches strategic initiative with Google Cloud to scale Gemini to global enterprises
March 27, 2024
Oriola partners with HCLTech to enhance customer experience through digital transformation
March 22, 2024
HCLTech boosts AI, ML offerings with new Microsoft Azure specializations
March 21, 2024